Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn’s disease

Table 3 Anti-phospholipid antibodies in patients with Crohn’s disease, ulcerative colitis, and healthy controls n (%)

	CD (n = 265)	UC (n = 186)	HC (n = 103)
Anti-β2-GPI IgG	5 (1.9)	4 (2.2)	2 (1.9)
Anti-β2-GPI IgM	8 (3.0)	12 (6.5)	3 (2.9)
Anti-β2-GPI IgA	7 (2.6)	7 (3.8)	3 (2.9)
Any anti-β2-GPI	19 (7.2)	18 (9.7)	8 (7.8)
ACA IgG	27 (10.2)bd	4 (2.2)d	2 (1.9)b
ACA IgM	8 (3.0)	4 (2.2)	1 (1.0)
ACA IgA	51 (19.2)bd	1 (0.5)d	0 (0.0)b
Any ACA	62 (23.4)bd	9 (4.8)d	3 (2.9)b
Anti-PS/PT IgG	20 (7.5)	9 (4.8)	9 (8.7)
Anti-PS/PT IgM	25 (9.4)bc	8 (4.3)c	1 (1.0)b
Anti-PS/PT IgA	24 (9.1)c	7 (3.8)c	9 (8.7)
Any anti-PS/PT	54 (20.4)d	19 (10.2)d	16 (15.5)

^bP < 0.01, CD vs controls;

^cP < 0.05,

^dP < 0.01, CD vs UC. Using χ²-test with Yates correction. APLA: Antiphospholipid antibodies; β2-GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: Phosphatidylserine/prothrombin complex; CD: Crohn’s disease; UC: Ulcerative colitis.